376 related articles for article (PubMed ID: 32630618)
21. Immunological and clinical implications of immune checkpoint blockade in human cancer.
Kim HD; Park SH
Arch Pharm Res; 2019 Jul; 42(7):567-581. PubMed ID: 30843144
[TBL] [Abstract][Full Text] [Related]
22. Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy.
Kouidhi S; Ben Ayed F; Benammar Elgaaied A
Front Immunol; 2018; 9():353. PubMed ID: 29527212
[TBL] [Abstract][Full Text] [Related]
23. Treg-mediated acquired resistance to immune checkpoint inhibitors.
Saleh R; Elkord E
Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
[TBL] [Abstract][Full Text] [Related]
24. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
25. Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies.
Wong RS; Ong RJ; Lim JS
Cancer Drug Resist; 2023; 6(4):768-787. PubMed ID: 38263984
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
27. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
Russell L; Peng KW; Russell SJ; Diaz RM
BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
[TBL] [Abstract][Full Text] [Related]
28. New Developments in T Cell Immunometabolism and Implications for Cancer Immunotherapy.
Oberholtzer N; Quinn KM; Chakraborty P; Mehrotra S
Cells; 2022 Feb; 11(4):. PubMed ID: 35203357
[TBL] [Abstract][Full Text] [Related]
29. Tumor-associated myeloid cells: new understandings on their metabolic regulation and their influence in cancer immunotherapy.
Porta C; Sica A; Riboldi E
FEBS J; 2018 Feb; 285(4):717-733. PubMed ID: 28985035
[TBL] [Abstract][Full Text] [Related]
30. Characteristics of the Tumor Microenvironment That Influence Immune Cell Functions: Hypoxia, Oxidative Stress, Metabolic Alterations.
Augustin RC; Delgoffe GM; Najjar YG
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33348579
[TBL] [Abstract][Full Text] [Related]
31. The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy.
Mpakali A; Stratikos E
Cancers (Basel); 2021 Jan; 13(1):. PubMed ID: 33406696
[TBL] [Abstract][Full Text] [Related]
32. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
Yang J; Chen J; Wei J; Liu X; Cho WC
Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
[TBL] [Abstract][Full Text] [Related]
33. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation.
Ferris RL; Lenz HJ; Trotta AM; García-Foncillas J; Schulten J; Audhuy F; Merlano M; Milano G
Cancer Treat Rev; 2018 Feb; 63():48-60. PubMed ID: 29223828
[TBL] [Abstract][Full Text] [Related]
34. New therapeutic targets for cancer: the interplay between immune and metabolic checkpoints and gut microbiota.
Agrawal B
Clin Transl Med; 2019 Aug; 8(1):23. PubMed ID: 31468283
[TBL] [Abstract][Full Text] [Related]
35. Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy.
Ohnuma K; Hatano R; Dang NH; Morimoto C
Mod Rheumatol; 2019 Sep; 29(5):721-732. PubMed ID: 30285531
[TBL] [Abstract][Full Text] [Related]
36. Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities.
Suresh K; Naidoo J; Lin CT; Danoff S
Chest; 2018 Dec; 154(6):1416-1423. PubMed ID: 30189190
[TBL] [Abstract][Full Text] [Related]
37. Metabolic Checkpoints: Novel Avenues for Immunotherapy of Cancer.
Shevchenko I; Bazhin AV
Front Immunol; 2018; 9():1816. PubMed ID: 30131808
[TBL] [Abstract][Full Text] [Related]
38. Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events.
Nakamura Y
Front Med (Lausanne); 2019; 6():119. PubMed ID: 31192215
[TBL] [Abstract][Full Text] [Related]
39. The Breakthroughs in Cancer Immune Checkpoint Based Therapy: A Review of Development in Immune Checkpoint Study and its Application.
Huang Y; Liang D; Liu J; Zeng J; Zeng Y
Comb Chem High Throughput Screen; 2017; 20(5):430-439. PubMed ID: 28302019
[TBL] [Abstract][Full Text] [Related]
40. Immunometabolism: A new target for improving cancer immunotherapy.
Guo C; Chen S; Liu W; Ma Y; Li J; Fisher PB; Fang X; Wang XY
Adv Cancer Res; 2019; 143():195-253. PubMed ID: 31202359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
